Journal: Journal of Molecular Histology

Article Title: Modified citrus pectin modulates splenic immune responses and galectin expression following cisplatin treatment in Wistar rats

doi: 10.1007/s10735-026-10828-w

Figure Lengend Snippet: Analysis of galectin expression in the spleen. A – D : Galectin-1 (Gal-1) immunoreactivity. E–H : Galectin-3 (Gal-3) immunoreactivity. I–L : Galectin-9 (Gal-9) immunoreactivity. Immunolabeling is observed in both white pulp (wp) and red pulp (rp), with differences in distribution and intensity among groups: SHAM (control animals), MCP (animals treated with MCP), CIS (animals treated with cisplatin), and MCP + CIS (animals treated with MCP and cisplatin). Counterstain: Carazzi’s hematoxylin. Scale bars: 100 μm. M–O : Densitometric analysis of Gal-1, Gal-3, and Gal-9 immunoreactivity in splenic tissue. Data represent the mean ± SEM of arbitrary units (a.u.) of protein expression ( n = 5 animals/group). * p < 0.05; ** p < 0.01, *** p < 0.001; **** p < 0.0001 (M, O, Q-S: ANOVA followed by post-hoc Tukey test; N: Kruskal-Wallis followed by post-hoc Dunn’s test)

Article Snippet: E–H : Galectin-3 (Gal-3) immunoreactivity.

Techniques: Expressing, Immunolabeling, Control

Journal: Journal of Molecular Histology

Article Title: Modified citrus pectin modulates splenic immune responses and galectin expression following cisplatin treatment in Wistar rats

doi: 10.1007/s10735-026-10828-w

Figure Lengend Snippet: Correlation analysis of galectin expression and splenic immune cell populations between CIS and MCP + CIS groups. A , B : Correlation analyses show no significant correlations between galectin expression (Gal-1, Gal-3, and Gal-9) and CD68⁺ macrophages or CD3⁺ T cells in the CIS group. C : Correlation analysis indicating positive associations between Gal-1, Gal-3, and Gal-9 expression and the CD68 + macrophage population in the MCP + CIS group. D : Correlation analysis showing a positive association between Gal-3 expression and CD3⁺ T cells in the MCP + CIS group. Correlation analyses were performed using Pearson or Spearman tests, depending on the data distribution ( n = 5 animals/group). * p < 0.05; *** p < 0.001; **** p < 0.0001

Article Snippet: E–H : Galectin-3 (Gal-3) immunoreactivity.

Techniques: Expressing

Journal: American Journal of Translational Research

Article Title: The combination of circRNA-UMAD1 and Galectin-3 in peripheral circulation is a co-biomarker for predicting lymph node metastasis of thyroid carcinoma

doi:

Figure Lengend Snippet: Circulating Gal3 is a potential target for the diagnosis of LNM. TCGA database analysis of the expression level of Gal3 in serval solid cancer indicated that Gal3 is 100% positive in thyroid cancer, which is more than the rate in other cancers (A). The protein level of Gal3 in the serum of PTC patients was detected by ELISA analysis, showing that LNM patients express more Gal3 (B). Gal3 expression is significantly related to LNM based on univariant analysis in 50 PTC patients (C). Sequencing TCGA data downloaded from the LinkedOmics website demonstrated that the RNA level of Gal3 is upregulated in tumor tissues (D), and is associated with the stage of PTC (E) and LNM (F). Unsupervised hierarchical clustering heat map shows the expression of different genes between non-LNM and LNM PTC samples (G). Unpaired t-test and One-way ANOVA multiple comparisons test were performed to obtain P values in comparisons of two or more groups. * indicates P<0.05.

Article Snippet: The membranes were incubated with primary antibodies specific to Gal3 (Cell Signaling, #87985), NOTCH1 (Cell Signaling, #3608), Hes1 (Cell Signaling, #11988), TGF-β1 (Abcam, ab92486), ErbB2 (Abcam, ab237715), ErbB4 (Abcam, ab19391), NF-κB (p65) (Abcam, ab7970) and GAPDH (Bioworld BS606030), also corresponding secondary HRP-conjugated goat anti-rabbit (Jackson.US) were immunoreacted.

Techniques: Biomarker Discovery, Expressing, Enzyme-linked Immunosorbent Assay, Sequencing

Journal: American Journal of Translational Research

Article Title: The combination of circRNA-UMAD1 and Galectin-3 in peripheral circulation is a co-biomarker for predicting lymph node metastasis of thyroid carcinoma

doi:

Figure Lengend Snippet: Relationship between Gal3 expression and pathological features in PTC patients with or without LNM

Article Snippet: The membranes were incubated with primary antibodies specific to Gal3 (Cell Signaling, #87985), NOTCH1 (Cell Signaling, #3608), Hes1 (Cell Signaling, #11988), TGF-β1 (Abcam, ab92486), ErbB2 (Abcam, ab237715), ErbB4 (Abcam, ab19391), NF-κB (p65) (Abcam, ab7970) and GAPDH (Bioworld BS606030), also corresponding secondary HRP-conjugated goat anti-rabbit (Jackson.US) were immunoreacted.

Techniques: Expressing

Journal: American Journal of Translational Research

Article Title: The combination of circRNA-UMAD1 and Galectin-3 in peripheral circulation is a co-biomarker for predicting lymph node metastasis of thyroid carcinoma

doi:

Figure Lengend Snippet: Enrichment of miRNA and circRNA sequencing profiles. Flow chart of the circRNA/miRNA/mRNA screen to identify regulators upstream of Gal3 (A). Pathological morphology was validated by HE staining of two paired primary and LNM tumor samples that were prepared for RNA sequencing (B). Unsupervised hierarchical clustering shows distinct miRNA (C) and circRNA (D) expression with green representing decreased expression. Significantly enriched pathways in genes regulated by differentially expressed cancer-related miRNAs (E) and circRNAs (F) were identified by KEGG pathway enrichment analysis. Western blot analysis for ErbB, NOTCH, NF-κB and TGF-β pathways (G). IF staining for Gal3 and ErbB4 in original tumor and Lymph node metastasis tissues (H). bar = 20 μm.

Article Snippet: The membranes were incubated with primary antibodies specific to Gal3 (Cell Signaling, #87985), NOTCH1 (Cell Signaling, #3608), Hes1 (Cell Signaling, #11988), TGF-β1 (Abcam, ab92486), ErbB2 (Abcam, ab237715), ErbB4 (Abcam, ab19391), NF-κB (p65) (Abcam, ab7970) and GAPDH (Bioworld BS606030), also corresponding secondary HRP-conjugated goat anti-rabbit (Jackson.US) were immunoreacted.

Techniques: Sequencing, Staining, RNA Sequencing, Expressing, Western Blot

Journal: American Journal of Translational Research

Article Title: The combination of circRNA-UMAD1 and Galectin-3 in peripheral circulation is a co-biomarker for predicting lymph node metastasis of thyroid carcinoma

doi:

Figure Lengend Snippet: miR-873 was identified to act as an upstream regulator of Gal3. Unsupervised hierarchical clustering heat map of miRNA expression fold-change from TCGA data shows the top 50 miRNAs with decreased expression in the LNM group. Nine miRNAs were consistent with our sequencing data, as shown by the black arrow (A). A Venn diagram showing that miR-873 is a potential regulator of Gal3 and is related to LNM in PTC (B). The putative binding site of miR-873-5p on Gal3 is shown, including the wild-type and mutated Gal3 3’-UTR sequences which were used to create the wild-type and mutant luciferase reporter constructs. The similarity between 12 putative complementary binding sites (red letters) of the Gal3 3’-UTRs from different species (C). A luciferase reporter assay demonstrated that miR-873 inhibited the transcription of the wild-type but not the mutant 3’-UTRs of Gal3 (D). The expression of endogenous Gal3 RNA was inhibited in miR-873-mimic-infected HEK293 cells compared to the control, as detected by qRT-PCR and normalized to GAPDH mRNA (E), while it was increased in the miR-873 inhibitor group (F). The RNA level of miR-873 was validated in LNM-positive tumor tissues compared to the negative control by analyzing the TCGA profile. N0: non-LNM; N1: LNM (G). miR-873 was validated again in a different metastatic lymph node group, N0: non-LNM; N1<4; 410 (H). Relative expression of miR-873 in circulation was detected by qRT-PCR between non-LNM and LNM patients (I). Unpaired t-test and one-way ANOVA multiple comparisons test were performed to obtain P values in comparisons of two or more groups. * indicates P<0.05.

Article Snippet: The membranes were incubated with primary antibodies specific to Gal3 (Cell Signaling, #87985), NOTCH1 (Cell Signaling, #3608), Hes1 (Cell Signaling, #11988), TGF-β1 (Abcam, ab92486), ErbB2 (Abcam, ab237715), ErbB4 (Abcam, ab19391), NF-κB (p65) (Abcam, ab7970) and GAPDH (Bioworld BS606030), also corresponding secondary HRP-conjugated goat anti-rabbit (Jackson.US) were immunoreacted.

Techniques: Expressing, Sequencing, Binding Assay, Mutagenesis, Luciferase, Construct, Reporter Assay, Infection, Control, Quantitative RT-PCR, Negative Control

Journal: American Journal of Translational Research

Article Title: The combination of circRNA-UMAD1 and Galectin-3 in peripheral circulation is a co-biomarker for predicting lymph node metastasis of thyroid carcinoma

doi:

Figure Lengend Snippet: CircRNA UMAD1 is associated with LNM and Gal3 expression. Expression of hsa-circ-UMAD1 quantified by at least three independent qRT-PCR experiments in the cohort comparing non-LNM tumors (absent, n = 23) and LNM tumors (present, n = 27). Unpaired t-tests were performed to identify significant differences. The relative expression level of circRNA UMAD1 was normalized to the level of β-actin (A). CircRNA UMAD1 expression was significantly related to LNM and primary side location based on univariant analysis of 50 PTC patients, which is described in Table 1 (B). The correlation between the expression of circRNA UMAD1 and Gal3 was evaluated by Person’s correlation test (r = 0.35, P = 0.00138) (C). All data are expressed as the median ± range with three independent experiments.

Article Snippet: The membranes were incubated with primary antibodies specific to Gal3 (Cell Signaling, #87985), NOTCH1 (Cell Signaling, #3608), Hes1 (Cell Signaling, #11988), TGF-β1 (Abcam, ab92486), ErbB2 (Abcam, ab237715), ErbB4 (Abcam, ab19391), NF-κB (p65) (Abcam, ab7970) and GAPDH (Bioworld BS606030), also corresponding secondary HRP-conjugated goat anti-rabbit (Jackson.US) were immunoreacted.

Techniques: Expressing, Quantitative RT-PCR

Journal: American Journal of Translational Research

Article Title: The combination of circRNA-UMAD1 and Galectin-3 in peripheral circulation is a co-biomarker for predicting lymph node metastasis of thyroid carcinoma

doi:

Figure Lengend Snippet: ROC curves for individual biomarkers circRNA UMAD1 and Gal3 or combination. ROC curve analysis of circRNA UMAD1 calculates the best cutoff point to discriminate between the LNM and primary tumor groups. The area under the curve (AUC) (SE) = 0.718 (0.072); 95% confidence interval was 0.576 to 0.86; P = 0.0084 (A). ROC curve analysis of Gal3 between these two groups. AUC (SE) = 0.825 (0.061); 95% confidence interval was 0.704 to 0.945; P<0.001 (B). ROC curve analysis of circRNA UMAD1 combined with Gal3 for distinguishing patients in the LNM vs. primary tumor groups. AUC (SE) = 0.87 (0.051); 95% confidence interval was 0.766 to 0.97; P<0.001 (C). Likelihood ratio = 3.75. P<0.01, ROC, receiver operating characteristic; SE, standard error.

Article Snippet: The membranes were incubated with primary antibodies specific to Gal3 (Cell Signaling, #87985), NOTCH1 (Cell Signaling, #3608), Hes1 (Cell Signaling, #11988), TGF-β1 (Abcam, ab92486), ErbB2 (Abcam, ab237715), ErbB4 (Abcam, ab19391), NF-κB (p65) (Abcam, ab7970) and GAPDH (Bioworld BS606030), also corresponding secondary HRP-conjugated goat anti-rabbit (Jackson.US) were immunoreacted.

Techniques: